HHS’ proposal to adopt the U.S. Pharmacopeia’s Medicare Part D formulary classification system to help evaluate the breadth of drug coverage offered by individual and small group private insurance plans, beginning in 2014, puts the USP formulary guidelines back in the spotlight for biopharmaceutical stakeholders.
HHS outlined the plan for using the USP guidelines in its proposed rule on “essential health benefits” (EHB) requirements for individual and small group plans. The proposal, which addresses drug...